BioCentury
ARTICLE | Clinical News

Simponi golimumab: Additional Phase III data

November 19, 2012 8:00 AM UTC

Additional data from the double-blind, international Phase III GO-FURTHER trial in 592 patients with active moderate to severe RA despite methotrexate treatment showed that 2 mg/kg IV Simponi given at weeks 0 and 4 and then every 8 weeks plus methotrexate significantly reduced mean van der Heijde-Sharp (vdH-S) score, an x-ray measure of joint destruction, from baseline to week 24 vs. placebo (0.03 vs. 1.09 points, p<0.001). At week 52, IV Simponi also significantly reduced mean vdH-S score from baseline vs. placebo (0.13 vs. 1.22 points, p<0.001). Mean change in total vdH-S score from week 24 to week 52 was 0.15 in the IV Simponi group vs. 0.12 in patients who crossed over from placebo to IV Simponi at week 24. Data were presented at the American College of Rheumatology meeting in Washington. ...